Group 1 - The core viewpoint of the news is that Jieko Biotech's application for the marketing authorization of Ranibizumab injection has been accepted by the National Medical Products Administration, supported by Yidu Technology's comprehensive clinical research services [1][2] - Age-related macular degeneration (AMD) is a leading cause of blindness in individuals aged 50 and above, with a prevalence rate of 13.36% among those over 60 in China, and wet AMD (wAMD) accounting for 13.42% of cases, with a blindness rate of approximately 90% [1][2] - Yidu Technology has established a strong foundation for clinical research through its AI medical infrastructure, having processed over 6 billion authorized medical records and covering more than 4,000 hospitals, which supports the ongoing Phase III clinical trial [2][3] Group 2 - Yidu Technology's service capabilities are enhanced by its expertise in ophthalmology, allowing for precise management of trial specifications and risks associated with wAMD, resulting in a patient dropout rate of only 15% and a shortened project cycle [3] - The company has established strategic partnerships with renowned ophthalmology experts and institutions, demonstrating its commitment to collaborative development in the medical and research fields [3] - As of March 31, 2025, Yidu Technology has completed 411 clinical studies, including 275 real-world research projects, showcasing its extensive experience in clinical research [3]

Group 1 - The U.S. has announced an increase in tariffs on imported steel and aluminum from 25% to 50%, causing a strong global reaction and leading to a drop in steel stocks in Asia [2] - South Korea's trade ministry held an emergency meeting with industry leaders to discuss the potential impact of these tariffs on steel exports, which accounted for 13.1% of South Korea's total steel exports in 2024 [2] - Major steel trading partners of the U.S., including Canada and the EU, condemned the tariff increase and warned of possible retaliatory measures [2] Group 2 - In June, brokerage firms have released their "golden stocks," with over a hundred stocks recommended, particularly in the machinery and pharmaceutical sectors [3] - The machinery sector is optimistic about investment opportunities arising from the development of controlled nuclear fusion, while the pharmaceutical sector suggests focusing on CXO, specialty raw materials, and pharmacies [3] Group 3 - The second round of negotiations between Russia and Ukraine concluded with an agreement to exchange the remains of fallen soldiers and a new round of prisoner swaps [4] - Russia plans to unilaterally transfer 6,000 fallen soldiers' remains to Ukraine next week, and both sides will establish a medical committee for regular exchanges of severely injured soldiers [4] Group 4 - A surge in interest around "stablecoins" has led to numerous broker calls focusing on this topic, with several stablecoin-related stocks showing strong performance [5] - Despite the potential applications of stablecoins, there are concerns about market speculation and a lack of in-depth research from major institutions [5] Group 5 - Insurance companies have been actively increasing their stakes in high-dividend assets, particularly bank stocks, with 15 instances of stake increases reported by seven insurance firms by the end of May [6] - The current wave of stake increases is driven by the need for stable cash returns in a low-interest-rate environment [6] Group 6 - An announcement from the White House indicated that the U.S. and China are expected to hold talks regarding tariff issues [7] - The U.S. International Trade Court has blocked a tariff policy announced by Trump, stating that such powers belong exclusively to Congress [7] Group 7 - An announcement from Annier indicated that the company is planning a change in control, with the current major shareholders proposing to transfer 13.03% of their shares to a counterparty [8][17] - The stock of Annier will be suspended from trading starting June 3, with the suspension expected to last no more than two trading days [8][17] Group 8 - BYD reported a total of 382,500 new energy vehicle sales in May 2025, with overseas sales accounting for 89,000 units [28] - BAIC BluePark's subsidiary saw a 215.11% year-on-year increase in sales in May 2025, totaling 17,100 units [29] - Great Wall Motors reported May sales of 102,200 vehicles, marking an 11.78% year-on-year increase, with 32,600 of those being new energy vehicles [30]

Core Viewpoint - The article summarizes significant announcements from various listed companies in the Shanghai and Shenzhen stock markets, highlighting key corporate actions and performance metrics that may present investment opportunities or insights into market trends [1]. Group 1: Corporate Actions - Hengbao Co., Ltd. disclosed that its controlling shareholder engaged in stock trading during a period of unusual price fluctuations, confirming that the actions were consistent with previously announced plans and not in violation of regulations [2]. - Lvtong Technology announced plans to acquire at least 51% of Jiangsu Damo Semiconductor Technology Co., aiming to expand into the semiconductor sector [3]. - Anner announced a potential change in control, with its major shareholders planning to transfer 13.03% of shares to a third party, leading to a temporary suspension of trading [3]. - Ruikang Pharmaceutical terminated a share transfer agreement due to significant changes in the external environment, which involved the transfer of 76 million shares [4]. - Tibet Mining is re-listing its 100% stake in Baiyin Zabuye Lithium Industry with a 10% price reduction due to a lack of qualified buyers in the first round [6]. - Guangdong Construction plans to acquire 100% equity in five solar power project companies for 471 million yuan, with expected net profits of approximately 52.91 million yuan in 2025 [7]. - Bangjie Co., Ltd. is undergoing a change in control, with a new major shareholder expected to optimize the company's main business structure [8]. Group 2: Performance Metrics - BYD reported May sales of 382,500 new energy vehicles, with a total production of 349,800 units [16]. - BAIC BluePark's subsidiary saw a 215.11% year-on-year increase in May sales, totaling 17,100 units [17]. - Great Wall Motors announced May sales of 102,200 vehicles, reflecting an 11.78% year-on-year growth, including 32,600 new energy vehicles [19]. Group 3: Government Subsidies - Tianfeng Securities received a government subsidy of 32.56 million yuan, representing 109.6% of its audited net profit for 2024 [12]. - Tiens Holdings announced a government subsidy of 195 million yuan related to its operational activities [13]. Group 4: Major Contracts - Longpan Technology signed a sales contract for lithium iron phosphate cathode materials, with a total sales value exceeding 5 billion yuan over the next several years [24]. - Jushen Co., Ltd. entered into a shipbuilding contract for two deck barges, with a total value of 78 million yuan [26].

Core Viewpoint - The announcement indicates that East China Pharmaceutical's subsidiary has received a notice of acceptance for the marketing authorization application of Ranibizumab injection, marking a significant progress in the drug's development [1] Company Summary - East China Pharmaceutical's wholly-owned subsidiary, Hangzhou Zhongmei East China Pharmaceutical Co., Ltd., has submitted a marketing authorization application for Ranibizumab injection, which has been accepted by the National Medical Products Administration [1] - The total investment in the research and development of Ranibizumab injection amounts to approximately 220 million yuan [1] - The acceptance of the application is an important milestone in the drug's development process, which is expected to enhance the company's core competitiveness in the treatment of various retinal diseases in the long term [1] Industry Summary - Ranibizumab injection is indicated for the treatment of various retinal diseases in adults and premature infants, highlighting its potential market relevance [1] - The acceptance of the marketing application is a positive development for the industry, as it reflects ongoing innovation and progress in the treatment of eye diseases [1]